JP2019517490A - がん療法のためのメトロノミック経口ゲムシタビン - Google Patents

がん療法のためのメトロノミック経口ゲムシタビン Download PDF

Info

Publication number
JP2019517490A
JP2019517490A JP2018562559A JP2018562559A JP2019517490A JP 2019517490 A JP2019517490 A JP 2019517490A JP 2018562559 A JP2018562559 A JP 2018562559A JP 2018562559 A JP2018562559 A JP 2018562559A JP 2019517490 A JP2019517490 A JP 2019517490A
Authority
JP
Japan
Prior art keywords
gem
formulation
tumor
gemcitabine
mtd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018562559A
Other languages
English (en)
Japanese (ja)
Inventor
ウェイ−ファ ハオ
ウェイ−ファ ハオ
シュー−ピイン シュエ
シュー−ピイン シュエ
チャン−シャン シュー
チャン−シャン シュー
Original Assignee
イノファーマックス インコーポレイテッド
イノファーマックス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イノファーマックス インコーポレイテッド, イノファーマックス インコーポレイテッド filed Critical イノファーマックス インコーポレイテッド
Publication of JP2019517490A publication Critical patent/JP2019517490A/ja
Priority to JP2022062568A priority Critical patent/JP2022088622A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2018562559A 2016-06-02 2017-06-02 がん療法のためのメトロノミック経口ゲムシタビン Pending JP2019517490A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022062568A JP2022088622A (ja) 2016-06-02 2022-04-04 がん療法のためのメトロノミック経口ゲムシタビン

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662344660P 2016-06-02 2016-06-02
US62/344,660 2016-06-02
PCT/CN2017/086942 WO2017206940A1 (en) 2016-06-02 2017-06-02 Metronomic oral gemcitabine for cancer therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022062568A Division JP2022088622A (ja) 2016-06-02 2022-04-04 がん療法のためのメトロノミック経口ゲムシタビン

Publications (1)

Publication Number Publication Date
JP2019517490A true JP2019517490A (ja) 2019-06-24

Family

ID=60479058

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018562559A Pending JP2019517490A (ja) 2016-06-02 2017-06-02 がん療法のためのメトロノミック経口ゲムシタビン
JP2022062568A Pending JP2022088622A (ja) 2016-06-02 2022-04-04 がん療法のためのメトロノミック経口ゲムシタビン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022062568A Pending JP2022088622A (ja) 2016-06-02 2022-04-04 がん療法のためのメトロノミック経口ゲムシタビン

Country Status (10)

Country Link
US (1) US10835548B2 (enExample)
EP (1) EP3463298B1 (enExample)
JP (2) JP2019517490A (enExample)
KR (1) KR102383824B1 (enExample)
CN (2) CN114224865A (enExample)
AU (1) AU2017273495B2 (enExample)
CA (1) CA3026144A1 (enExample)
ES (1) ES2898024T3 (enExample)
TW (1) TWI814703B (enExample)
WO (1) WO2017206940A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3980023A4 (en) * 2019-06-06 2023-08-02 Board of Regents, The University of Texas System LIPID NANOPARTICLES CONTAINING PHARMACEUTICALS AND/OR NUTRACEUTICALS AND RELATED METHODS

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012524820A (ja) * 2009-04-27 2012-10-18 イノファーマックス インコーポレイテッド 親水性薬剤の自己マイクロエマルジョン化経口医薬組成物およびその調製方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
CA2598239C (en) 2005-02-18 2019-10-29 Abraxis Bioscience, Inc. Nanoparticulate formulations of taxanes and carrier proteins for use in combination chemotherapy
AU2009297091B2 (en) 2008-09-23 2015-03-05 Nektar Therapeutics Compositions and methods for achieving sustained therapeutic drug concentrations in a subject
WO2010039039A1 (en) * 2008-10-03 2010-04-08 Clavis Pharma Asa Oral formulations of gemcitabine derivatives
CN101926779A (zh) * 2010-08-19 2010-12-29 苏州特瑞药业有限公司 一种吉西他滨固体脂质纳米粒及其制备方法与用途
WO2013058294A1 (ja) * 2011-10-18 2013-04-25 味の素株式会社 膵臓癌及び／又は胆道癌治療薬
US20150283237A1 (en) 2014-04-02 2015-10-08 Mitchell S. Felder Ctla-4 blockade with metronomic chemotherapy for the treatment of cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012524820A (ja) * 2009-04-27 2012-10-18 イノファーマックス インコーポレイテッド 親水性薬剤の自己マイクロエマルジョン化経口医薬組成物およびその調製方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BRITISH JOURNAL OF CANCER, vol. 103, JPN6021006834, 2010, pages 52 - 60, ISSN: 0004833845 *
CANCER RESEARCH, AACR, ANNUAL MEETING, vol. Vol. 75, Issue 15, JPN6021006836, 2015, pages 4506, ISSN: 0004833846 *
CANCER THERAPY: CLINICAL, vol. Vol. 14, Issue 11, JPN6021051979, 2008, pages 3477 - 3486, ISSN: 0004833844 *
MOL. CANCER THER., vol. Vol. 7, Issue 3, JPN6021006838, 2008, pages 638 - 647, ISSN: 0004833847 *

Also Published As

Publication number Publication date
EP3463298A1 (en) 2019-04-10
CA3026144A1 (en) 2017-12-07
CN109310631A (zh) 2019-02-05
KR102383824B1 (ko) 2022-04-06
EP3463298B1 (en) 2021-09-01
KR20190015420A (ko) 2019-02-13
TW201808309A (zh) 2018-03-16
WO2017206940A1 (en) 2017-12-07
ES2898024T3 (es) 2022-03-03
US10835548B2 (en) 2020-11-17
US20170348341A1 (en) 2017-12-07
AU2017273495B2 (en) 2023-01-12
TWI814703B (zh) 2023-09-11
CN114224865A (zh) 2022-03-25
JP2022088622A (ja) 2022-06-14
EP3463298A4 (en) 2020-01-01
AU2017273495A1 (en) 2018-12-20

Similar Documents

Publication Publication Date Title
ES2762250T5 (es) Tratamiento combinado del cáncer
TWI764943B (zh) 一種抗pd-1抗體和vegfr抑制劑聯合在製備治療癌症的藥物中的用途
ES2909741T3 (es) Tratamiento del cáncer
WO2015187194A1 (en) Use of paclitaxel particles
ES3023754T3 (en) Terlipressin composition for use in treating ascites
ES2983643T3 (es) Terapia oral con tridecanoato de testosterona
KR20210005714A (ko) 비스플루오로알킬-1,4-벤조디아제피논 화합물을 포함하는 조합 조성물 및 이의 사용 방법
KR20210008527A (ko) 비스플루오로알킬-1,4-벤조디아제피논 화합물을 포함하는 조성물 및 이의 사용 방법
TW201141473A (en) Combination therapy for small cell lung cancer
US10080807B2 (en) Combination chemotherapy comprising a liposomal prodrug of mitomycin C
CN105283178A (zh) 用于治疗癌症的包含mps-1激酶抑制剂和有丝分裂抑制剂的组合
JP2022088622A (ja) がん療法のためのメトロノミック経口ゲムシタビン
US20160317540A1 (en) Therapeutic Treatment
JP2022088622A5 (enExample)
EP2034957A2 (en) Pharmaceutical composition for oral administration
US20060269596A1 (en) Controlled release compositions comprising an acylanilide
HK1193771A (en) Therapeutic treatment
NZ616410B2 (en) Combination treatment of cancer

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200326

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210302

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210531

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210729

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210902

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220106

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220726